Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine in MDS Post-HMA Failure
NCT02159872Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2015
- Primary completion
- Apr 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started May 2015; status: completed.
02
Drugs
homoharringtonine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02159872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159872.